1. Healthcare IPOs - 2012
Selected VC-backed healthcare IPOs in 2012; Market caps greater than $100M*
Offer Value ($M) * Company Exchange:Ticker Selected Venture Investors
08/02/2012 $1,000 Globus Medical NYSE:GMED Clarus, SunAmerica Ventures
10/10/2012 $566 Intercept Pharmaceuticals NasdaqGM:ICPT OrbiMed
10/10/2012 $477 Kythera Biopharmaceuticals NasdaqGS:KYTH Arch, Prospect, Versant, JAFCO
06/27/2012 $467 Tesaro NasdaqGS:TSRO NEA, InterWest, KPCB
02/08/2012 $392 ChemoCentryx NasdaqGS:CCXI Alta, OrbiMed, HealthCap
04/30/2012 $217 Supernus Pharmaceuticals NasdaqGM:SUPN NEA, Abingworth, OrbiMed
07/25/2012 $188 Hyperion Therapeutics NasdaqGM:HPTX NEA, Bay City, Highland, Sofinnova Ventures, Panorama
01/26/2012 $186 Verastem NasdaqGM:VSTM ATV, Bessemer, Cardinal Partners, MPM, Longwood
07/18/2012 $153 Durata Therapeutics NasdaqGM:DRTX Canaan, Domain, Sofinnova Ventures, Quaker BioVentures, Aisling, New Leaf
02/03/2012 $151 Cempra NasdaqGM:CEMP Intersouth, Blackboard, Sofinnova Ventures, Quaker BioVentures, Aisling, Devon Park
03/28/2012 $110 DBV Technologies S.A. ENXTPA:DBV Sofinnova Partners
$3,907M across 11 companies
Source: Company filings, press releases, Capital IQ, VentureSource, and the 451 Group.
* Market cap as of December 21, 2012. The market caps of acquired companies are based on acquisition values.
New Enterprise Associates 1/3 1/2/2013

2. Healthcare Acquisitions - 2012
Selected VC-backed healthcare M&A in 2012, greater than $100M
Announced Value ($M) Company Acquiror Selected Venture Investors
May 21 $4,693 HealthCare Partners DaVita Summit Partners
Apr 30 $4,204 Gen-Probe Hologic KPCB, Wellington Management Company
Jan 07 $2,579 Inhibitex Bristol-Myers Squibb NEA, OrbiMed, CDP Capital, ATV, Essex Woodlands
May 02 $1,525 Fougera Pharmaceuticals Sandoz New Leaf
Mar 08 $1,350 Cameron Health Boston Scientific Alloy Ventures, Delphi, Versant
Jan 26 $1,016 Micromet Amgen SV Life Sciences, Kingsbridge Capital
Jan 26 $925 Avila Therapeutics Celgene Abingworth, Advent Venture; Atlas, Polaris
Sep 27 $731 China Kanghui Holdings Medtronic Vivo Ventures
Apr 26 $700 EUSA Pharma Jazz Pharmaceuticals Essex Woodlands, SV Life Sciences
Oct 22 $680 NextWave Pharmaceuticals Pfizer Bay City, Vivo Ventures, Perseus, Sofinnova Ventures, Aisling, Panorama, Kearny
Jun 21 $565 U.S. Renal Care Leonard Green Salix, SV Life Sciences
Feb 14 $563 Stromedix Biogen Idec Atlas, Bessemer, Frazier, Red Abbey, New Leaf
Jun 04 $517 AscendHealth Corporation Universal Health Services CHL, Polaris, Three Arch Partners
Mar 26 $492 ISTA Pharmaceuticals Bausch & Lomb Sanderling Ventures, New Leaf
Dec 12 $483 YM BioSciences Gilead Sciences NEA
Feb 09 $472 United Surgical Partners Europe Doughty Hanson Barclays Ventures
May 13 $435 Extend Health Towers Watson Psilos, Health Evolution Partners
Aug 30 $430 Sunovion Respiratory Development Sunovion Pharmaceuticals Canaan, TPG Growth, Novo A/S, Mesa Verde, TPG Biotech
Nov 08 $425 Vessix Vascular Boston Scientific OrbiMed
Dec 10 $415 deCODE genetics Amgen Arch, Polaris
Dec 12 $390 Incline Therapeutics The Medicines Company Frazier, 5AM Ventures
Nov 19 $377 BioMimetic Therapeutics Wright Medical Group InterWest, Novo A/S
Nov 16 $375 SkinMedica Allergan Domain, HealthCare Ventures
Dec 10 $364 Curanum AG Korian Deutschland Triton
Apr 10 $330 KAI Pharmaceuticals Amgen Delphi, Intersouth Partners, InterWest, Kearny
Mar 15 $320 Ferrokin Biosciences Shire Burrill, Clarus
Mar 19 $314 superDimension Covidien Concord, Oxford Bioscience, Mi3, Pitango, OrbiMed
Jan 04 $273 Cardiokine Cornerstone Therapeutics Advent Venture, Burrill, HealthCare Ventures, Perseus, Aisling
Dec 26 $270 CVIngenuity Covidien NEA
Oct 08 $265 Rhythmia Medical Boston Scientific Norwich Ventures
Feb 03 $208 Topaz Pharmaceuticals Sanofi Pasteur Perseus, Fidelity Investments, Aisling, Beacon Bioventures
Apr 12 $172 Pervasis Therapeutics Shire Highland, Flagship, Polaris
Oct 23 $165 NeoMend CR Bard Vivo Ventures, Prospect, Sanderling Ventures, Novo A/S, Clarus
Mar 05 $154 Epitomics Abcam Sycamore
Nov 14 $152 Cypress Pharmaceutical Pernix Therapeutics TA Associates
May 14 $150 EKR Therapeutics Cornerstone Therapeutics MPM, Quaker BioVentures
Nov 06 $140 Envoy Therapeutics Takeda America 5AM Ventures
Sep 17 $133 Complete Genomics BGI Enterprise Partners, Essex Woodlands, OVP, Prospect, OrbiMed, Highland
$27,750M across 38 companies
Source: Company filings, press releases, Capital IQ, VentureSource.
Note: Restricted to M&A exits greater than $100M.
New Enterprise Associates 2/3 1/2/2013

3. VCs Listed by Number of Exits in 2012 (Healthcare)
16 venture firms with at least 3 healthcare IPOs or acquisitions valued >$100M during 2012
VC IPOs/M&A Selected Companies
OrbiMed 8 Intercept Pharmaceuticals, ChemoCentryx, Supernus Pharmaceuticals, Supernus Pharmaceuticals, Inhibitex, Vessix Vascular, superDimension, Complete Genomics
NEA 6 Tesaro, Supernus Pharmaceuticals, Hyperion Therapeutics, Inhibitex, YM BioSciences, CVIngenuity
Aisling 5 Durata Therapeutics, Cempra, NextWave Pharmaceuticals, Cardiokine, Topaz Pharmaceuticals
New Leaf 4 Durata Therapeutics, Fougera Pharmaceuticals, Stromedix, ISTA Pharmaceuticals
Sofinnova Ventures 4 Hyperion Therapeutics, Durata Therapeutics, Cempra, NextWave Pharmaceuticals
Clarus 3 Globus Medical, Ferrokin Biosciences, NeoMend
Essex Woodlands 3 Inhibitex, EUSA Pharma, Complete Genomics
Highland 3 Hyperion Therapeutics, Pervasis Therapeutics, Complete Genomics
InterWest 3 Tesaro, BioMimetic Therapeutics, KAI Pharmaceuticals
Perseus 3 NextWave Pharmaceuticals, Cardiokine, Topaz Pharmaceuticals
Polaris 3 Avila Therapeutics, deCODE genetics, Pervasis Therapeutics
Prospect 3 Kythera Biopharmaceuticals, NeoMend, Complete Genomics
Quaker BioVenture 3 Durata Therapeutics, Cempra, EKR Therapeutics
SV Life Sciences 3 Micromet, EUSA Pharma, U.S. Renal Care
Vivo Ventures 3 China Kanghui Holdings, NextWave Pharmaceuticals, NeoMend
Novo A/S 3 Sunovion Respiratory Development, BioMimetic Therapeutics, NeoMend
Source: Company filings, press releases, Capital IQ, VentureSource
Note: Restricted to M&A exits and IPOs greater than $100M
New Enterprise Associates 3/3 1/2/2013